KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
April 18 2018 - 7:30AM
Business Wire
– Oral Plasma Kallikrein Inhibitor Data in a
Preclinical Model of Retinal Edema to be Presented –
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
announced that data in support of KalVista’s ongoing development in
diabetic macular edema (DME) has been accepted for oral
presentation at The Association for Research in Vision and
Ophthalmology (ARVO) 2018 Annual Meeting on May 1, 2018 in
Honolulu, Hawaii.
“We look forward to presenting oral plasma kallikrein inhibitor
data at ARVO 2018,” said Andrew Crockett, Chief Executive Officer
of KalVista. “The potential to treat retinal edema orally would be
a groundbreaking option for patients and we are pleased to share
these findings with the medical and patient communities.”
The oral presentation details are as follows:
- Novel Oral Plasma Kallikrein (PKal)
Inhibitor KV123833 Blocks VEGF-Mediated Retinal Vascular
Hyperpermeability in a Murine Model of Retinal
Edema Session: Neovascularization and Vascular
Permeability, #365 Session Date/Start Time: May 1, 2018
at 3:45 PM in Room 314
About KalVista Pharmaceuticals, Inc.KalVista
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which,
in excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of
novel, small molecule plasma kallikrein inhibitors initially
targeting hereditary angioedema (HAE) and diabetic macular edema
(DME). The Company has created a structurally diverse portfolio of
oral plasma kallikrein inhibitors, and is advancing multiple drug
candidates into Phase 1 clinical trials for HAE. KalVista’s most
advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, has successfully completed its
first-in-human study in patients with DME and began a Phase 2
clinical trial in 2017.
For more information, please visit www.kalvista.com.
Forward-Looking StatementsThis press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties
that could cause actual results to differ materially from what we
expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical
trial timing and results. Further information on potential risk
factors that could affect our business and its financial results
are detailed in the annual report on Form 10-K filed on July 27,
2017, our most recent Quarterly Report on Form 10-Q, and other
reports as filed from time to time with the Securities and
Exchange Commission. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180418005143/en/
KalVista Pharmaceuticals, Inc.Leah Monteiro,
857-999-0808Director, Corporate Communications & Investor
Relationsleah.monteiro@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Aug 2024 to Sep 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Sep 2023 to Sep 2024